Form 4: Vaxart Director David Wheadon Reports Acquisition of Shares and Stock Options

Director David Wheadon reports acquisition of 16,000 common stock shares and 95,400 stock options in Vaxart, Inc.

Summary

• On June 11, 2024, David E. Wheadon, a director of Vaxart, Inc., reported acquiring 16,000 shares of common stock.
• These shares were obtained through the vesting of restricted stock units.
• Wheadon also acquired 95,400 stock options with an exercise price of $0.77.
• The stock options vest on the earlier of the date immediately prior of the 2025 annual meeting of stockholders of the Issuer and June 11, 2025, the first anniversary of the date of the grant.
• Following these transactions, Wheadon directly owns 30,750 shares of common stock and 95,400 stock options.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition of shares and options by a director could be seen as a mildly positive signal, but it's not definitively bullish.

Positives

• The acquisition of shares and stock options by a director could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's sentiment and alignment with shareholder interests.

Stakeholder Impact

• Shareholders may view the director's acquisition of shares and options as a positive sign of confidence in the company's future.

Key Dates